3B Blackbio DX Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q2 FY26.
3B

3B Blackbio DX Ltd

Q2 FY26Healthcare Services

3B Blackbio DX Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹34Cr
+17.2% YoY
+54.5% QoQ
Net profit
₹15Cr
0% YoY
+15.4% QoQ
Margin
43%
−12 pp YoY
−10 pp QoQ

3B Blackbio DX Ltd Q2 FY26 key numbers

Revenue
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25.

As stated in 3B Blackbio DX Ltd's Q2 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on 3B Blackbio DX Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,406
Market cap₹1.1K Cr
P/E20.4

The short version

Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. H1 EBITDA (3B standalone) increased from ₹3,387.70 Lakh (H1 FY 2024-25) to ₹3,618.54 Lakh (H1 FY 2025-26).

From 3B Blackbio DX Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25.
  • Exports in Q2 FY 2025-26: ₹496.71 Lakh vs. ₹366.50 Lakh in Q2 FY 2024-25.
  • TRUPCR Europe Ltd (TPE) Q2 sales: GBP 404,900 vs. GBP 420,435 last year, slight decrease due to summer holidays.
  • H1 FY 2025-26 revenue from operations: ₹4151.99 Lakh vs. ₹5038.89 Lakh in H1 FY 2024-25 (3B standalone MDx business).
  • Consolidated H1 2025-26 revenue: ₹5613.67 Lakh vs. ₹4858.10 Lakh previous year.
  • Export growth projected at 20–25%.
  • TPE full-year growth expected at 20–25%.

2 more points from 3B Blackbio DX Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company acquired Coris BioConcept SRL, Belgium, for £2.15M upfront plus £0.615M earn-out, completed on August 29, 2025, marking its first acquisition to strengthen market credibility (Page 29, 42).
  • Other sections focus on organic growth, marketing, contracts, and international expansion.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • It mentions "strong order inflow" from the Middle East, indicating growing market traction (Page 21).
  • Signing of long-term contracts (2-3 years) covering 20%-25% of total revenue under the Reagent-Rental Model demonstrates stability and steady business (Page 41).
  • The Coris BioConcept acquisition is expected to contribute improved sales and positive EBITDA in H2, tied to its contracts including a €1.0 million government project in Belgium supplied in Nov-Dec (Page 29).
  • The company has secured annual rate contracts in the Middle East, Southeast Asia, and Europe (Page 21).

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

3B Blackbio DX Ltd Q2 FY26 results — key figures

3B Blackbio DX Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue3429+17.2%22+54.5%
Operating profit (EBITDA)1516-6.2%12+25%
Operating margin43%55%-12 pp53%-10 pp
Profit before tax2019+5.3%16+25%
Net profit (PAT)15150%13+15.4%
EPS (₹)17.1417.07+0.4%14.67+16.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Maitreya Medicare (Q2 FY26)

    23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.

  • Metropolis Healt (Q2 FY26)

    Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…

  • Unihealth Hosp (Q2 FY26)

    Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…

  • Indegene (Q2 FY26)

    Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q2 FY26 results?

Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. H1 EBITDA (3B standalone) increased from ₹3,387.70 Lakh (H1 FY 2024-25) to ₹3,618.54 Lakh (H1 FY 2025-26).

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company acquired Coris BioConcept SRL, Belgium, for £2.15M upfront plus £0.615M earn-out, completed on August 29, 2025, marking its first acquisition to strengthen market credibility (Page 29, 42).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.